Importantly, this group demonstrated that CMPD1 works in EGFR-enhanced GBM cells, which tend to be more aggressive and radio/chemoresistant, supporting tubulins including TUBB4 as an important target for adjuvant therapy when chemoresistance to TMZ develops over time. The gene discussed is SOX9; the disease is glioblastoma.